|
LB/O99: 48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy (Global Hepatitis Summit 2023 Paris April 28)
|
|
|
![0502231](../images/050223/050223-1/0502231.gif)
![0502232](../images/050223/050223-1/0502232.gif)
![0502233](../images/050223/050223-1/0502233.gif)
![0502234](../images/050223/050223-1/0502234.gif)
![0502235](../images/050223/050223-1/0502235.gif)
![0502236](../images/050223/050223-1/0502236.gif)
![0502237](../images/050223/050223-1/0502237.gif)
|
|
|
|
|
|
|